Lilly wins new approval for Forteo-WEB ONLY
Eli Lilly and Co. has won U.S. regulatory approval to market its slow-selling osteoporosis drug Forteo for a new use, Lilly announced today.Lilly can now promote Forteo as a therapy for men and women who regularly take medicines called glucocorticoids for rheumatory arthritis or obstructive lung disease. Sustained use of glucocorticoids cause bone fractures in […]